Korsana Biosciences Inc. (KRSA)
NASDAQ: KRSAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
KRSA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.71B
- EPS (TTM)
- -$16.14
- Dividend yield
- None
- 52-week range
- 7.19 – 59.36
- Day range
- 34.51 – 39.41
- Volume / Avg
- 265.23K / 119.71K
- Beta
- —
- Shares outstanding
- 45.54M
52-week range
KRSA stock today
Korsana Biosciences (KRSA) closed at $37.56 on Nov 20, up 5.95% (+$2.11), versus the S&P 500's 3.70% decline. Volume was 2.2x the average at 265.23K shares, a sign of unusually heavy trading. Shares are 36.7% below their 52-week high of $59.36, set on Apr 1, 2026 and 422.5% above the 52-week low of $7.19, in the middle of the past year's range.
KRSA is up 322.5% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 262.5%. Korsana Biosciences has posted a net loss over the last twelve months (EPS of -$16.14), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Korsana Biosciences
Company profileKorsana Biosciences, Inc. develops therapeutic antibodies for the treatment of neurodegenerative diseases. The company has developed Therapeutic Targeting (THETA), a blood-brain barrier-penetrant shuttle platform designed to enhance central nervous system exposure of investigational therapies and enable delivery of large therapeutic molecules across the blood-brain barrier into the central nervous system.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Jonathan Violin M.B.A., Ph.D.
- Headquarters
- Waltham, MA
- Employees
- 19
- Website
- korsana.com
Financial highlights
Full financialsIn fiscal 2025, Korsana Biosciences generated $2.1 million in revenue, up 3.7% from fiscal 2024, its 2nd consecutive year of revenue growth. Korsana Biosciences reported a net loss of $3.5 million, compared with a loss of $3.1 million a year earlier. Operating margin was -239.8%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $2.07M | $2.00M | $0 | $297.00K | $3.94M |
| Growth | +3.70% | — | -100.00% | -92.47% | +71.69% |
| Net income | $-3.53M | $-3.06M | $-5.26M | $-44.08M | $-51.65M |
| EPS (diluted) | $-1.11 | $-1.21 | $-2.25 | $-20.28 | $-1.32 |
Analyst forecast
ForecastConsensus (5 analysts)
strong_buy
Avg. price target
$44.00+17.15%
- Strong buy 0
- Buy 5
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 11, 2026
- EPS actual vs est.
- $-3.19 vs $-0.78
- Surprise
- -308.97%
KRSA news
All KRSA newsKorsana Biosciences peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| SDGRSchrodinger Inc. | 22.93 | -12.95% | $1.72B | vs KRSA |
| RAREUltragenyx Pharmaceutical Inc. | 16.48 | -4.30% | $1.68B | vs KRSA |
| BRVEBraveheart Bio Inc. | 20.39 | +5.81% | $1.67B | vs KRSA |
| TRAXFirst Tracks Biotherapeutics Inc. | 41.64 | -6.34% | $1.75B | vs KRSA |
| STOKStoke Therapeutics Inc. | 26.81 | -0.45% | $1.75B | vs KRSA |
| ETONEton Pharmaceuticals Inc. | 60.85 | -0.83% | $1.76B | vs KRSA |
| AGIOAgios Pharmaceuticals Inc. | 27.60 | -4.03% | $1.65B | vs KRSA |
| ZBIOZenas BioPharma Inc. | 23.85 | -4.75% | $1.62B | vs KRSA |
Indexes, lists and sector
Korsana Biosciences stock FAQ
What is Korsana Biosciences's stock price today?
KRSA last traded at $37.56 as of Nov 20, 4:00 PM EST, up 5.95% on the day. Prices are delayed at least 15 minutes.
Does Korsana Biosciences pay a dividend?
No. Korsana Biosciences does not currently pay a regular cash dividend.
Who is Korsana Biosciences's CEO?
Dr. Jonathan Violin M.B.A., Ph.D. is the chief executive officer of Korsana Biosciences Inc., which has about 19 employees.
Has KRSA ever split its stock?
Yes. The most recent KRSA stock split was a 1-for-7 split on Sep 9, 2026, one of 2 splits on record.
What is the KRSA 52-week high?
The 52-week high for KRSA is $59.36 and the 52-week low is $7.19. The stock is currently 36.7% below its high.